SPECT images were acquired on a Discovery NM/CT 670 Pro (GE Healthcare, Chicago, Illinois, USA) using a low‐energy, high‐resolution collimator, noncircular orbit, step‐and‐shoot mode, 128 views (64 per camera head), and 20 s per view. Image reconstruction was performed using Evolution (GE Healthcare, Chicago, Illinois, USA), an ordered subsets expectation maximization (OSEM) algorithm incorporating collimator–detector response, attenuation and scatter correction, as well as resolution recovery. Images were reconstructed with nine iterations and 10 subsets, and a 128 × 128 matrices (voxel size of 4.42 × 4.42 × 4.42 mm3).18 After reconstruction, the Q.Metrix software package (GE Healthcare, Chicago, Illinois, USA), automatically resampled both the CT and the SPECT images to a voxel size of 2.21 × 2.21 × 2.21 mm3 prior to delineation. After the SPECT acquisition, low‐dose CT images were acquired (100 kVp; auto tube current modulation of 100 mA) for the purpose of attenuation correction.
Discovery nm ct 670 pro
Manufactured by GE Healthcare
Sourced in United States, Israel
The Discovery NM/CT 670 Pro is a versatile medical imaging system that combines single-photon emission computed tomography (SPECT) and computed tomography (CT) technologies. It is designed to provide high-quality diagnostic images for a wide range of clinical applications.
Automatically generated - may contain errors
Lab products found in correlation
Biograph mct flow, by Siemens (1 mentions)
Symbia t2, by Siemens (1 mentions)
Biograph mmr, by Siemens (1 mentions)
Jetstream workstation, by Philips (1 mentions)
Xeleris workstation, by GE Healthcare (1 mentions)
Xeleris 3.0 workstation, by GE Healthcare (1 mentions)
Precedence 6, by Philips (1 mentions)
Symbia intevo 6, by Siemens (1 mentions)
Optima ct540, by GE Healthcare (1 mentions)
22 protocols using discovery nm ct 670 pro
1
SPECT Imaging Protocol with Detailed Reconstruction
2
Bone SPECT Imaging of Prostate Cancer Metastases
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Bone SPECT data in the areas (1–2 SPECT steps) covering metastatic sites of bone were obtained from 15 patients with prostate cancer 3 h after intravenous injection of 740 MBq of Tc-99m hydroxymethylene diphosphonate (Tc-99m HMDP) using a combined SPECT/CT system (Discovery NM/CT 670pro, GE Healthcare, Milwaukee, WI, USA). The acquisition protocol was as follows: 60 steps of 12 s/step, 360 degrees, a matrix of 128 × 128, low-energy high-resolution collimator, main energy window at 141 keV ± 10%, and sub energy window at 120 keV ± 5%. Low-dose X-ray CT was performed for CTAC.
3
Imaging Protocol for [99mTc]Tc-N4-BTG
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All scans were obtained on a GE Discovery NM/CT 670 Pro (GE Healthcare, Milwaukee, USA) SPECT/CT system, equipped with a LEHR collimator and operating within an energy window of 140.5 keV ± 10%. A scatter window ranging from 114 to 126 keV was additionally acquired for planar and SPECT imaging. For SPECT, the imaging field of view was from neck to upper thighs. At each bed position, 60 views were acquired, with a duration of 8 s each. Subsequently, images were reconstructed using an ordered subset expectation maximisation (OSEM) algorithm (2 iterations and 10 subsets) with a Butterworth filter (fc = 0.48, n = 10). Scatter and attenuation correction was applied. For whole-body planar imaging, a scan speed of 30 cm/min was employed until 60 min post-injection, after which the acquisition speed was moderated to 12 cm/min for any further data collection. Planar imaging was performed at 5 and 30 min after injection of the radiopharmaceutical. At 60, 120, and 240 min after injection additional SPECT/CT and planar imaging was acquired. An overview of the imaging protocol can be found in Fig. 2 . For the scans at 5 and 30 min after injection, no micturition took place. Subsequently, the patients were asked to void their bladder directly prior to each examination. No blood samples were taken.
![]()
Imaging protocol for [99mTc]Tc-N4-BTG.
4
Preoperative Lymphatic Mapping with 99mTc-SC
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
A dual-head SPECT/CT scanner with low-energy high-resolution collimators (Discovery NM/CT 670 Pro, GE Healthcare, USA) was used. Each patient was given a peritumoral intradermal injection of 9.25 MBq (0.25 mCi) ±10% of 99mTc-SC (Beijing Shihong Co. Ltd; Beijing, China) for surgery planned on the same day or twice the dose (0.5 mCi) for surgery arranged the next day. Planar scintigraphy (PS) was acquired after 20 min (within 4 h), after the injection of the radiotracer, with 3-minute static images in the anterior and lateral projections (matrix 256 × 256, zoom 1), followed by SPECT/CT (matrix 128 × 128, zoom 1) with the patient lying supine as well as arms positioned above the head. Images were processed by OSEM (ordered-subset expectation maximization) reconstruction and attenuation correction.
5
Thyroid Imaging with 99mTc-MIBI SPECT/CT
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The imaging device was a GE Discovery NM/CT670pro single photon emission tomography (SPECT/CT) scanner with a low-energy, high-resolution collimator, a 128 × 128 acquisition matrix, an energy peak setting of 140keV, a 20% acquisition window width, a magnification of 2.57, and an acquisition time of 10 minutes per image. No special preparation was required before the examination, and patients were placed in the supine position with the field of view from the neck to the upper chest. The 99mTc-MIBI imaging agent (provided by Atomic High-Tech Co., Ltd., radiochemical purity > 95%) was injected intravenously with 15mCi, and the static image of the anterior neck was obtained in the early phase (15 minutes) and the delayed phase (120 minutes). The image was reconstructed by computed tomography and the 99mTc-MIBI biphasic image was obtained.
6
Whole-Body Bone Scan for Bone Metastasis Detection
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
A total of 617 patients from April 15th, 2019 to May 29th, 2020 with suspected bone metastasis and underwent whole-body bone scan were retrospectively analyzed. The studies involving human participants were reviewed and approved by Institutional Review Board of the Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Union Hospital, and the requirement to obtain informed consent was waived.
The whole-body bone scans were obtained 3–4 h after an intravenous injection of 740–1110 MBq 99mTc-methylene diphosphonate (99mTc-MDP; purchased from Guangzhou HTA Co. Ltd.) with a γ-camera equipped with low-energy, high-resolution parallel-hole collimators (GE Discovery NM/CT 670 Pro; scan speed, 20 cm/min; matrix, 256 × 1024). DICOM images with 16 bit depth included both anterior and posterior views. The ground truth segmentation of lesion and skeleton were annotated by board certificated physicians.
The anterior and posterior images were divided into two groups and processed separately. Similar processing method was used in these two sets of images. Therefore, only the process of anterior image will be described below for simplicity.
The whole-body bone scans were obtained 3–4 h after an intravenous injection of 740–1110 MBq 99mTc-methylene diphosphonate (99mTc-MDP; purchased from Guangzhou HTA Co. Ltd.) with a γ-camera equipped with low-energy, high-resolution parallel-hole collimators (GE Discovery NM/CT 670 Pro; scan speed, 20 cm/min; matrix, 256 × 1024). DICOM images with 16 bit depth included both anterior and posterior views. The ground truth segmentation of lesion and skeleton were annotated by board certificated physicians.
The anterior and posterior images were divided into two groups and processed separately. Similar processing method was used in these two sets of images. Therefore, only the process of anterior image will be described below for simplicity.
7
Quantitative Bone Imaging with SPECT/CT
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
The bone scans were performed using a SPECT/CT system (Discovery NM/CT 670 Pro; GE Healthcare, Chicago, IL, USA) equipped with a low-energy high-resolution (LEHR) collimator 3 hours after an intravenous injection of 736.3±22.2 MBq (19.9±0.6 mCi) 99mTc-MDP, corresponding to 12.21±1.85 MBq (0.33±0.05 mCi/kg). A planar scan over the anterior and posterior regions of the whole body was first performed using the LEHR collimator at 256×256 pixels (Fig. 1 ). Next, a quantitative SPECT scan with the LEHR collimator was performed at a matrix of 128×128 pixels, a step-and-shoot mode for 15 seconds per frame, and 360 rotations for every 6° view angle for the two detectors. Low-dose CT scan images were then acquired using adaptive dose modulation with 5-mm slice thickness at 120 kVp and 20 mAs.
8
Phantom Measurements for 161Tb Imaging
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All phantom measurements were performed using a Discovery NM/CT 670 Pro (GE Healthcare, Chicago , IL, US A) γ-camera. An energy spectrum was acquired for visualization of the photon emissions from 161Tb. The emission- and scatter-energy windows used are shown in Table 3 . The lowest and highest emission windows were referred to as EM1 and EM2, respectively, while the scatter windows at the lowest and highest energy were referred to as SC1 and SC2, respectively. The center energies of EM1 and EM2 were equivalent to γ-emission energies of 48.9 and 74.6 keV, respectively.
9
Evaluating Bone Metastasis with SPECT/CT
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
From May 2013 to July 2014, whole-body bone scintigraphy with technetium-99m hydroxymethylene diphosphonate (Tc-99m HMDP) showed hypermetabolic sites in 318 patients. These patients underwent this imaging test because of initial staging (n = 82) and suspected bone metastasis (n = 236). To further evaluate the abnormal sites, bone SPECT and CT using integrated SPECT/CT systems (Discovery NM/CT 670pro, GE Healthcare) consisting of SPECT scanner and 16-slice multidetector CT were performed in the areas (1–3 SPECT steps) covering the hypermetabolic sites. SPECT/CT scans were performed as a part of bone scintigraphic test or dual tests of bone scintigraphy and diagnostic CT. Regarding the bone scintigraphic test alone, low-dose CT for attenuation correction was added to bone SPECT and used for image fusion. Image noise in low-dose CT is improved with recently developed iterative reconstruction algorithms (about 1 mGy of volume CT dose index (CTDIvol)) while maintaining its image contrast. Regarding the dual tests, diagnostic CT was also performed just after the acquisition of bone SPECT in an identical position (5–13 mGy of CTDIvol).
10
Dual Tracer Imaging of Thyroid Diseases
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Thyrotropin alfa was administered 48 and 24 h before the administration of [18F]TFB and [131I]iodine. A median activity of 317.0 [63.0] MBq [18F]TFB was administered intravenously. The PET acquisition was initiated 40 min after tracer injection (Biograph mCT flow or Biograph mMR, Siemens Healthineers, Erlangen, Germany; acquisition speed: 2 min/bed position or 1.1 mm/s). Low-dose CT or MRI was acquired for attenuation correction of PET data. A median activity of 315.0 [516.8] MBq [131I]iodine was administered immediately after completion of the PET acquisition (a month delayed in one patient; only patient #12 received a therapeutic dosage of 3 GBq [131I]iodine). WBS and SPECT-CT acquisitions were done in accordance with guidelines (Discovery NM/CT 670 Pro, GE Healthcare, Chalfont St Giles, GB or Symbia T2, Siemens Healthineers, Erlangen, Germany) [17 (link)].
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!